Verzenios, with the active ingredient abemaciclib, is a prescription medication used in the treatment of certain types of breast cancer. Specifically, it is designed for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Verzenios works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes that promote the growth of cancer cells. By blocking these enzymes, Verzenios can slow down the progression of the disease. It is often used in combination with other therapies, such as hormone therapy, to enhance treatment effectiveness. As with any medication, it is important to use Verzenios under the guidance of a healthcare professional to ensure proper management of its benefits and potential side effects.